Iron overload is a risk factor for zygomycosis

被引:39
作者
McNab, AA
McKelvie, P
机构
[1] ROYAL VICTORIAN EYE & EAR HOSP,MELBOURNE,VIC 3002,AUSTRALIA
[2] ST VINCENTS HOSP,DEPT ANAT PATHOL,MELBOURNE,VIC,AUSTRALIA
关键词
D O I
10.1001/archopht.1997.01100160089018
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Well-recognized risk factors for zygomycosis include diabetic ketoacidosis, immunocompromise, and deferoxamine therapy for iron or aluminum overload, usually in patients undergoing kidney dialysis. We report a case of fatal nasal-orbital-cerebral zygomycosis in an 82-year-old man with known myelodysplasia and well-controlled diabetes. He was not receiving deferoxamine. Despite radical surgery and amphotericin B therapy, he died; primary hemochromatosis with gross iron overload was found post mortem. Experimental evidence suggests iron overload without deferoxamine therapy may be a risk factor for zygomycosis; the findings in this case would support this hypothesis.
引用
收藏
页码:919 / 921
页数:3
相关论文
共 6 条
[1]   EFFECTS OF IRON AND DESFERRIOXAMINE ON RHIZOPUS INFECTION [J].
ABE, F ;
INABA, H ;
KATOH, T ;
HOTCHI, M .
MYCOPATHOLOGIA, 1990, 110 (02) :87-91
[2]  
ARTIS WM, 1982, DIABETES, V31, P109
[3]   DEFEROXAMINE THERAPY AND MUCORMYCOSIS IN DIALYSIS PATIENTS - REPORT OF AN INTERNATIONAL REGISTRY [J].
BOELAERT, JR ;
FENVES, AZ ;
COBURN, JW .
AMERICAN JOURNAL OF KIDNEY DISEASES, 1991, 18 (06) :660-667
[4]   FATAL MUCORMYCOSIS THERAPY ASSOCIATED WITH DEFEROXAMINE [J].
SLADE, MP ;
MCNAB, AA .
AMERICAN JOURNAL OF OPHTHALMOLOGY, 1991, 112 (05) :594-595
[5]   EFFECTS OF DEFEROXAMINE, FEROXAMINE AND IRON ON EXPERIMENTAL MUCORMYCOSIS (ZYGOMYCOSIS) [J].
VANCUTSEM, J ;
BOELAERT, JR .
KIDNEY INTERNATIONAL, 1989, 36 (06) :1061-1068
[6]   SURVIVAL FACTORS IN RHINO-ORBITAL-CEREBRAL MUCORMYCOSIS [J].
YOHAI, RA ;
BULLOCK, JD ;
AZIZ, AA ;
MARKERT, RJ .
SURVEY OF OPHTHALMOLOGY, 1994, 39 (01) :3-22